Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death
Brent R. Logan, … , Philip R. Gafken, Sophie Paczesny
Brent R. Logan, … , Philip R. Gafken, Sophie Paczesny
Published August 1, 2023
Citation Information: J Clin Invest. 2023;133(15):e168575. https://doi.org/10.1172/JCI168575.
View: Text | PDF
Clinical Research and Public Health

Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death

Abstract

BACKGROUND Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic hematopoietic cell transplantation (HCT). More accurate information regarding the risk of developing cGVHD is required. Bone marrow (BM) grafts contribute to lower cGVHD, which creates a dispute over whether risk biomarker scores should be used for peripheral blood (PB) and BM.METHODS Day 90 plasma proteomics from PB and BM recipients developing cGVHD revealed 5 risk markers that were added to 8 previous cGVHD markers to screen 982 HCT samples of 2 multicenter Blood and Marrow Transplant Clinical Trials Network (BMTCTN) cohorts. Each marker was tested for its association with cause-specific hazard ratios (HRs) of cGVHD using Cox-proportional-hazards models. We paired these clinical studies with biomarker measurements in a mouse model of cGVHD.RESULTS Spearman correlations between DKK3 and MMP3 were significant in both cohorts. In BMTCTN 0201 multivariate analyses, PB recipients with 1-log increase in CXCL9 and DKK3 were 1.3 times (95% CI: 1.1–1.4, P = 0.001) and 1.9 times (95%CI: 1.1–3.2, P = 0.019) and BM recipients with 1-log increase in CXCL10 and MMP3 were 1.3 times (95%CI: 1.0–1.6, P = 0.018 and P = 0.023) more likely to develop cGVHD. In BMTCTN 1202, PB patients with high CXCL9 and MMP3 were 1.1 times (95%CI: 1.0–1.2, P = 0.037) and 1.2 times (95%CI: 1.0–1.3, P = 0.009) more likely to develop cGVHD. PB patients with high biomarkers had increased likelihood to develop cGVHD in both cohorts (22%–32% versus 8%–12%, P = 0.002 and P < 0.001, respectively). Mice showed elevated circulating biomarkers before the signs of cGVHD.CONCLUSION Biomarker levels at 3 months after HCT identify patients at risk for cGVHD occurrence.FUNDING NIH grants R01CA168814, R21HL139934, P01CA158505, T32AI007313, and R01CA264921.

Authors

Brent R. Logan, Denggang Fu, Alan Howard, Mingwei Fei, Jianqun Kou, Morgan R. Little, Djamilatou Adom, Fathima A. Mohamed, Bruce R. Blazar, Philip R. Gafken, Sophie Paczesny

×

Figure 1

Cumulative incidences of cGVHD by high and low biomarker scores in BMTCTN 0201 and 1202 cohorts for PB and BM recipients.

Options: View larger image (or click on image) Download as PowerPoint
Cumulative incidences of cGVHD by high and low biomarker scores in BMTCT...
Curves comparing high versus low biomarker scores (above and below the median cutpoint): (A) in PB patients from BMTCTN 0201 cohort, score including CXCL9+MMP3+DKK3, P = 0.002; (B) in BM patients from BMTCTN 0201 cohort, score including MMP3+clinical, P < 0.001; (C) in PB patients from BMTCTN 1202 cohort, score including CXCL9+MMP3+DKK3, P = 0.012; (D) in BM patients from BMTCTN 1202 cohort, score including MMP3+clinical, P = 0.002.